Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.
Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Why Pfizer’s BRAFTOVI results could reshape first-line treatment for BRAF-mutant mCRC
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.